



Institute  
and Faculty  
of Actuaries



# Clinical implications of AMR

Meghan Perry

MBCChB, MRCP, DTM&H, PhD

# Clinical implications

- Increased treatment failure
- Increased morbidity & mortality
- Decreased efficacy of antibiotic prophylaxis
  
- Need for improved clinical surveillance and data sharing
  
- Requirement for behavioural change


# Areas of clinical concern

- Communicable diseases due to bacteria
  - Tuberculosis
  - Sexually transmitted diseases
  - Respiratory tract infections
  - Diarrhoea caused by bacteria
  - Health care-associated infections
- Endogenous bacterial infections
  - Urinary tract infections
  - Skin and soft tissue infections
  - Infective endocarditis
  - Sepsis
- Prophylaxis
  - Burns, wounds
  - Caesarean sections
  - Joint replacements
  - Cancer therapy
  - Organ transplants




**IHME**  
Institute for Health Metrics  
and Evaluation

# How AMR occurs



# How AMR spreads



**Simply using antibiotics creates resistance. These drugs should only be used to treat infections.**

# Increasing antibiotic consumption





Figure 1: Global antibiotic consumption by class in 2000 and 2010  
Standard units are defined as a single dose unit (ie, pill, capsule, or ampoule).

# How are antibiotics chosen?

- Clinical diagnosis
- Local guidelines
- (Economic considerations)
- Antimicrobial susceptibility testing
  - Culture
  - Molecular

# Hypothetical clinical pathway





# Inadequate initial antimicrobial therapy (IIAT)

- Increased morbidity
  - Suppurative complications
  - Sepsis
- 3-fold increased mortality
- Prolonged hospitalisation
- Higher hospital costs
- Increased risk of transmission



# Carbapenem-resistant *Enterobacteriaceae*

- Carbapenems 'last-line' antibiotics
- 45% increase in global consumption between 2000 and 2010
- CRE often requires treatment with older toxic antibiotics
- Mortality rates 29 to 52 %



**Acute trust toolkit for the early detection,  
management and control of  
carbapenemase-producing  
*Enterobacteriaceae***

# Efficacy of antibiotic prophylaxis





Figure 1: Absolute risk reduction (ARR) of infection with antibiotic prophylaxis in common surgical procedures and blood cancer chemotherapy in the USA

- Estimated US levels of resistance to routine prophylaxis:
  - 39-51% of surgical infections
  - 27% post chemotherapy infections


# Predicted effect of AMR on prophylaxis



**Figure 3: Number of additional deaths per year in the USA under four scenarios of decreased efficacy of antibiotic prophylaxis**

# AMR surveillance - WHO

- Global survey of national resistance data
- Estimates of resistance rates in common bacteria in all WHO regions
- Significant gaps in resistance surveillance
- Lack of standard methodology
- Lack of data sharing




# Burden of AMR – published estimates




## ECDC

- EU in 2009
  - 5 bacterial infections
- 25K deaths per yr  
→ 400K illnesses



## CDC

- US in 2013
  - 16 bacterial infections
- 23K deaths per yr  
→ 2M illnesses




## O'Neill Review

- Global in 2013
  - Extrapolated from US + WHO estimates for TB
- 700K deaths per yr

# AMR burden

‘number of deaths attributable to the failure of antibiotic therapy due to antibiotic resistance’



# Measuring global clinical implications

- AMR is a global, not a local concern
  - New Delhi metallo- $\beta$ -lactamase (NDM-1)
- Lack of access to antimicrobials still a significant issue
- Global standardized antimicrobial surveillance network – WHO
- Data collection and sharing
  - measurement of rates of IAT
  - ? use of ICD-10 codes
  - ‘attributable burden’



# Requirement for behavioural change


- Education
- Infection control
- Avoidance of inappropriate treatment
- Targeted antibiotic therapy
- Improved stewardship

**NHS England launches national programme to combat antibiotic overusage**

🕒 10 March 2016 - 19:46

**NHS England has today launched the world's largest healthcare incentive scheme for hospitals, family doctors and other health service providers to prevent the growing problem of antibiotic resistance.**

# There is hope...



Source: C3XIP 2015

# Acknowledgements



- Mark Woolhouse, Catriona Waugh and EpiGroup, University of Edinburgh



- Regional Infectious Diseases Unit, Western General Hospital, Edinburgh



# Questions




# Comments

Expressions of individual views by members of the Institute and Faculty of Actuaries and its staff are encouraged.

The views expressed in this presentation are those of the presenter.

Crude infectious disease mortality rate in the United States, 1900–1996



# Formatting your presentation

## Page setup

- This presentation is set to A4 document size. Do not reset the size to any other screen size
- Do not alter anything in the master slides.

## Type and typography

- Only use the font Arial and never use type smaller than 10pt
- Headings and sub-headings should always be in gold and body copy and chart text should always be dark grey
- Page titles are pre-set to gold. Page text, text blocks and chart text are pre-set in the correct dark grey
- Top level bullets should be round and second level bullets should be dashes. Further levels should alternate accordingly
- Always write in sentence case unless a proper noun is used and do not use ampersands (&)
- Only use a full stop at the end of a bullet list.

## Content styling

- A selection of different title slides is offered, all accessible via the layout tab
- Do not use clip art. If you need guidance regarding imagery please consult the brand guidelines.

## Colour palette

The full colour palette is to the left hand side of every slide. Do not use non-palette colours.

**Please delete this slide after use.**